A 5-year-old boy had recurrent vomiting and lethargy with lacticacidemia and ketoacidemia since birth. Lipoamide dehydrogenase deficiency was found in muscle and fibroblasts. Therapy with sodium dichioroacetate, thiamine, and carnitine was associated with reduction of the severity and frequency of the decompensation episodes and near normal plasma lactate levels. At 5 years of age, the patient has normal cognitive function and moderate motor impair ment. (J Pediatr 1995;126:72-4)
Inborn errors of metabolism associated with combined lac ticacidemia and ketoacidemia usually cause life-threaten ing metabolic decompensation in infancy. In many cases the primary enzymatic defect can be localized to the pyruvate dehydrogenase complex or to the mitochondrial respiratory chain. The most common defect in the PDHC resides in its El subunit; deficiency of the E3 subunit (lipoamide dehy drogenase) has been reported in only a few patients,1"5 whose clinical course was characterized by progressive neurologic deterioration; most died during early childhood.
W e describe a 5-year-old boy with LAD deficiency who has been treated for the past 3 years with sodium dichioro acetate, thiamine, and carnitine. His cognitive functions were age appropriate, but his motor development was mod erately impaired. 
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Plasma lactate levels were determined in 15 samples be fore therapy was started and in 66 samples during therapy. Urinary organic acids were identified with a Hewlett-Pack ard 5970 mass selective detector as previously described. 6 In muscle homogenate, the activities of rotenone-sensitive NADH:ubiquinone oxidoreductase, antimycine-sensitive succinate:cytochrome c oxidoreductase, cytochrome c oxidase, citrate synthase, PDHC, the El subunit, LAD, and a-ketoglutarate dehydrogenase complex were determined according to previously described methods. Five patients with LAD deficiency have been reported.1'5 All had severe neurologic damage early in life. Their clin ical course was characterized by frequent episodes of met abolic decompensation and slow neurologic deterioration. Therapy with thiamine, glutamine, biotin, lipoic acid, restriction of branched-chain amino acids, and a lowcarbohydrate, high-fat diet did not seem to influence their neurologic course; only lipoic acid was reported to be of some biochemical benefit. Three patients died at 7 to 21 months of age, and two remained severely retarded.
For the past 3 years our patient has been treated with DCA, thiamine, and carnitine. During this period the frequency and severity of his decompensation episodes decreased markedly, and his plasma lactate concentration was maintained at nearly normal levels. N o adverse effects of this therapy have been observed, and at 5 years of age his cognitive functions were age appropriate, whereas his motor development was moderately impaired. The rea son for this favorable outcome is unclear, DCA is effective in lowering plasma lactate levels, but its administration has not been associated with improvement of preexisting neurologic damage.11 Our patient had only mild neurolo gic impairment when therapy was initiated. In view of the normal level of cerebrospinal fluid lactate and the normal results on neuroimaging and neurophysiologic studies, the possibility of a high residual LAD activity in the central nervous system cannot be excluded. We speculate that the main contribution of this therapy was preventive, by reduc ing the frequency and severity of the decompensation epi sodes. In previously described patients with LAD defi ciency, such events worsened preexisting neurologic dam age.4, 5 We conclude that DCA administration may be of benefit in children with LAD deficiency for the control of plasma lactate values and the attenuation of frequency and sever ity of decompensation episodes.
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